ocular hypertension and primary open-angle glaucoma
Ophthalmology · 2012–2012
2decisions
1medicine
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tafluprost for the treatment of ocular hypertension and primary open-angle glaucoma | Mar 2012 | Recommended with restriction | no section in document |
| tafluprost Treatment of ocular hypertension and primary open-angle glaucoma, as monotherapy or adjunctive therapy. | Mar 2012 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.